Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.62 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | CDC42 | P60953 | 1/20 | 0.62 |
| ▸ | RAC1 | P63000 | 1/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.54 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640494 | 1.00 | ABCB11 (0.65) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL29365195 | 1.00 | ABCB11 (0.65) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL15701616 | 0.98 | ABCB11 (0.62) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL30986302 | 0.88 | ABCB11 (0.57) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL20398797 | 0.87 | ABCB11 (0.65) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL23255697 | 0.83 | ABCB11 (0.66) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL23255694 | 0.83 | ABCB11 (0.61) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL7955027 | 0.83 | ABCB11 (0.61) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL23255698 | 0.83 | ABCB11 (0.61) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL9120097 | 0.83 | ABCB11 (0.66) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5286902-A | Process for preparation of 2-(6-methoxy-2-naphthyl)propionic acid and intermediates therefor utilizing 2,6-diisopropylnaphthalene | KOCH INDUSTRIES, INC. (US) | 1994-02-15 | — | — | US | claimed |
| WO-2024062319-A1 | POLYMERS WITH DUAL THERAPEUTIC AGENTS | Sony Group Corporation (JP) | 2024-03-28 | — | — | WO | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| WO-2023214325-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS | NOVARTIS AG (CH) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023209722-A1 | COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE | RAMBAM MED-TECH LTD. (IL) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023001045-A9 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海椿安生物医药科技有限公司 | 2023-10-26 | — | — | WO | disclosed |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4238571-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | OnQuality Pharmaceuticals China Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| US-20230272382-A1 | COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES | BANK OF AMERICA, N.A. | 2023-08-31 | — | — | US | disclosed |
| EP-1626065-A1 | Resin composition, method of its composition, and cured formulation | Nippon Shokubai Co., Ltd. (JP) | 2006-02-15 | — | — | EP | disclosed |
| US-20060029811-A1 | mixing a phenolic compound containing the inorganic microfine particle(SiO2) and a compound containing at least one of the glycidyl group and/or an epoxy group containing the inorganic microfine particle; fireproofing; good mechanical properties; heat resistance; automobiles, construction, electronics | NIPPON SHOKUBAI CO., LTD. (JP) | 2006-02-09 | — | — | US | disclosed |
| WO-2005085161-A1 | METHOD FOR PRODUCING AROMATIC ALKOXY KETONES | Rütgers Chemicals AG (DE) | 2005-09-15 | — | — | WO | disclosed |
| EP-0961765-A2 | PREPARATION OF CARBOXYLIC COMPOUNDS AND THEIR DERIVATIVES | ALBEMARLE CORPORATION (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1999032474-A1 | BENZOFURANS AND BENZOPYRANS AS CYTOPROTECTIVE AGENTS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998030529-A2 | PREPARATION OF CARBOXYLIC COMPOUNDS AND THEIR DERIVATIVES | ALBEMARLE CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
| US-5286902-A | Process for preparation of 2-(6-methoxy-2-naphthyl)propionic acid and intermediates therefor utilizing 2,6-diisopropylnaphthalene | KOCH INDUSTRIES, INC. (US) | 1994-02-15 | — | — | US | disclosed |
| EP-0386848-A1 | Novel Exophiala species | GIST-BROCADES N.V. (NL) | 1990-09-12 | — | — | EP | disclosed |
| EP-0205215-B1 | PROCESS FOR THE PREPARATION OF 2-ARYLPROPIONIC ACIDS | GIST-BROCADES N.V. (NL) | 1990-08-08 | — | — | EP | disclosed |
| EP-0205215-A2 | Process for the preparation of 2-arylpropionic acids | GIST-BROCADES N.V. (NL) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | ABCB11 1778/4885AKR1C3 2912/4885AKR1C2 2772/4885 |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MYOF, MYO3A, MYO3B | ABCB11 4826/4885AKR1C3 4356/4885AKR1C2 3755/4885 |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | TTR, MTPN, CRYAA | ABCB11 3420/4885AKR1C3 2062/4885AKR1C2 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.